Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Two New IntraOp’s Mobetron In China

IntraOp Medical Corporation announced two new orders for its Mobetron system from its Chinese distribution partner, Hui Long New Technology Co. LTD.

IntraOp’s Mobetron is a mobile technology which delivers IOERT(Intra-Operative Electron-beam Radiation Therapy) to a tumor site during cancer surgery. The Mobetron enables surgical and radiation oncologists to pinpoint the optimal site for radiation so as to deliver an effective dose during the procedure. Doctors are able to move the device among operating rooms (ORs) to treat number of patients more effectively and efficiently as the Mobetron is a mobile and self-shielded device.

The order marks the fifth and sixth Mobetrons sold in China. Its been twelve months since installing and utilizing the first device and oncologists in China have had a notable success with IOERT thus inspiring other centers to follow suit. IntraOp earlier this year sold and shipped Mobetrons to two Shanghai medical facilities. This order of two Mobetrons is for hospitals and should be ready for installation early next year.

Peter Yu, IntraOp’s Director of Far East Operations, noted, “With the very high patient loads our oncologists experience here in China, IOERT is often the only way to ensure that some patients are getting the radiation therapy treatment they need in a reasonable amount of time. With this order, we will be able to satisfy our customers’ growing demand for a device that will enable them to deliver IOERT in the OR.”

IntraOp CEO John Powers added, “This order represents our fifth and sixth Mobetron sale in China in just 18 months. This adoption rate demonstrates China’s willingness to leap frog old technologies, while quickly adopting and standardizing on new technologies proven to provide superior outcomes. We are incredibly optimistic about this adoption rate and the Mobetron’s potential to benefit cancer patients.”